Eunomia perspective · 2026-03-30 · Third-Party Due Diligence & Supply Chain Compliance

From Risk to Resilience: Why Third-Party Risk Management Is Pharma’s Biggest Competitive Advantage

Published by Eunomia Pharma Services · Updated 29 September 2026

Why does third-party risk management matter for pharma expanding into Europe?

Because responsibility does not transfer with outsourcing. Distributors, agents and vendors make market entry possible, but obligations under national transparency rules, the ABPI and EFPIA Codes, GDPR and anti-bribery law stay with the company. Without structured oversight, third-party execution can drift from company standards.

Building third-party oversight

Risk-rate third parties by country, activity and interaction with HCPs.
Carry out proportionate due diligence before onboarding.
Include compliance, audit and termination clauses in contracts.
Monitor higher-risk third parties after onboarding and capture their transfers of value.

The practical steps above are Eunomia’s operational guidance. See the source notes below for the scope of the external references.

Pharmaceutical and biotechnology companies rarely expand across borders alone. Distributors, service providers, local agents, logistics partners, and medical engagement vendors make rapid geographic growth possible. For small and mid-sized organisations in particular, third parties are often the bridge between innovation and international presence. They enable market entry into Europe without the need to build a full local infrastructure from day one.

However, the same partnerships that accelerate growth can also introduce the most significant compliance exposure a company faces.

Across Europe, regulators expect companies to remain accountable for activities performed on their behalf. Whether obligations arise from national transparency requirements, the UK ABPI Code, the EFPIA Code, data protection expectations under GDPR, or anti-bribery frameworks, responsibility does not transfer with outsourcing. It stays with the company. This makes third-party risk management not just a governance exercise, but a strategic capability.

The Expanding Role of Third Parties in European Market Entry

Emerging pharma and biotech companies frequently rely on distributors and local commercial partners to support early access programmes, promotional execution, logistics coordination, and stakeholder engagement. This approach allows organisations to establish a presence across multiple jurisdictions simultaneously while conserving internal resources.

However, European expansion is rarely uniform. Regulatory expectations differ between markets such as the UK, Germany, Italy, Spain, and Central and Eastern Europe. Transparency reporting frameworks, interactions with healthcare professionals, and requirements related to sponsorship or educational support vary significantly. Without structured oversight, third-party execution can unintentionally diverge from company standards.

This creates a critical question for leadership teams. How can organisations scale quickly without increasing compliance exposure?

Key Risk Areas When Working With Third Parties

Third-party risk in the pharmaceutical sector extends beyond contractual performance. It sits at the intersection of compliance, governance, and reputation.

One major exposure relates to anti-corruption risk. Many organisations use indicators such as the Transparency International Corruption Perceptions Index to inform risk classification across jurisdictions. Markets with higher perceived corruption risk often require enhanced due diligence, stronger documentation expectations, and closer monitoring. This becomes particularly relevant when distributors engage healthcare professionals on behalf of the company.

Promotional compliance is another important consideration. Distributors may adapt materials locally or interact with healthcare professionals independently. Without alignment to company standards and applicable national codes, even well-intentioned activities can create regulatory risk.

Transparency reporting obligations also introduce complexity. Transfers of value to healthcare professionals must often be captured accurately across multiple reporting frameworks. When responsibilities between sponsor companies and distributors are unclear, reporting gaps can emerge.

Pharmacovigilance obligations represent a further critical area. Third parties interacting with patients or healthcare professionals must understand how to recognise and escalate adverse events promptly. Weak escalation pathways can create regulatory exposure beyond the commercial function.

Finally, data protection expectations under GDPR require careful handling of personal data across borders. Third-party vendors frequently process sensitive information during event management, patient engagement, or support services. Without defined safeguards, this creates operational and legal risk.

Best Practices That Strengthen Third-Party Risk Management

Effective third-party oversight begins with structured risk-based due diligence. This should move beyond screening exercises and include assessment of ownership transparency, organisational governance, compliance maturity, and familiarity with local regulatory frameworks.

Risk classification models are particularly valuable when entering multiple European markets simultaneously. Organisations increasingly combine external indicators such as corruption perception indices with internal activity-based risk scoring to determine the level of oversight required.

Training plays an equally important role. Third parties should understand expectations around promotional compliance, transparency reporting, adverse event escalation, and interactions with patient organisations. Clear training programmes reduce ambiguity and strengthen accountability across distributed teams.

A well-defined RACI structure supports consistent execution across headquarters, affiliates, and distributors. Responsibility for approvals, reporting, monitoring, and escalation should never rely on assumptions. Clarity supports speed as well as compliance.

Monitoring then ensures that expectations remain embedded in practice. Risk-based monitoring may include documentation reviews, activity sampling, contract compliance checks, and periodic audits. When implemented proportionately, monitoring strengthens partnerships rather than restricting them.

Policies and procedures provide the operational backbone for this framework. They translate regulatory expectations into repeatable processes that support consistent expansion across markets.

Turning Risk Management into a Competitive Advantage

Strong third-party governance is no longer only about preventing enforcement action. It is increasingly recognised as an enabler of sustainable growth.

Companies with structured oversight frameworks are better positioned to enter new markets, engage healthcare systems confidently, and respond effectively to regulatory inspections. Investors and strategic partners also expect to see evidence that governance keeps pace with geographic expansion.

In practice, resilient third-party frameworks allow organisations to scale faster because expectations are already defined.

How Eunomia Pharma Services Supports Third-Party Risk Management Frameworks

At Eunomia Pharma Services, we support pharmaceutical and biotechnology companies in designing practical third-party governance frameworks tailored to European regulatory expectations.

This includes development of risk-based due diligence models aligned with market entry strategies, creation of distributor oversight procedures, and the implementation of monitoring approaches proportionate to organisational size and footprint. We also support the design of training programmes that help distributors and service providers understand their responsibilities clearly.

Importantly, we help organisations establish governance structures that define roles across headquarters and regional teams, ensuring that accountability remains visible as companies scale.

By embedding structured third-party oversight early in the expansion journey, organisations can move from reactive compliance management to proactive risk resilience. In a sector where trust underpins every partnership, this shift represents a meaningful competitive advantage

Sources and scope

UK Bribery Act 2010, section 7
The corporate offence of failing to prevent bribery by associated persons.
Ministry of Justice: Bribery Act 2010 guidance
UK guidance on adequate procedures to prevent bribery; it is not a healthcare-specific checklist.

External sources accessed 29 September 2026. Check the applicable country rules and current source text for a specific engagement.